Skip to main content
Contact
Locations
Search
Menu
Practices
Back
Overview
Accounting
Antitrust & Competition
Bankruptcy & Insolvency
Class Certification
Commercial Disputes
Damages
Data Science & Statistical Modeling
Energy, Climate & Natural Resources
Environmental, Social & Governance (ESG)
ERISA
Government & Corporate Investigations
Health Care
HEOR, Epidemiology & Market Access
Insurance
Intellectual Property
International Arbitration
Labor & Employment
Media, Entertainment & Communications
Privacy & Data Security
Securities, Financial Products & Institutions
Strategy, Policy & Analytics
Surveys & Experimental Studies
Tax
Technology
Transaction & Governance Litigation
Valuation
See full list of Practices & Focus Areas
Search our site
People
Insights
Back
Overview
Cases
AG Features
Videos
Publishing
Forum
Health Care Bulletin
News & Events
Back
Overview
News
Events
About
Back
Overview
Our Work
Locations
Diversity, Equity & Inclusion
Pro Bono
Careers
Back
Overview
Career Path
What Is Economic Consulting?
Why Analysis Group?
FAQs
Publishing
Insights
Publishing
The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas
Curr Med Res Opin. 2015 Mar; 31(3):537-45
View abstract
Authors
Macalalad AR, McAuliffe M,
Yang H
, Kageleiry A, Zhong Y,
Wu EQ
, Shonukan O, Bonthapally V.
Practices
HEOR, Epidemiology & Market Access
Collapse
Search our site